Bradykinin Type 1 Receptor – Inducible Nitric Oxide Synthase: A New Axis Implicated in Diabetic Retinopathy

Compelling evidence suggests a role for the inducible nitric oxide synthase, iNOS, and the bradykinin type 1 receptor (B1R) in diabetic retinopathy, including a possible control of the expression and activity of iNOS by B1R. In diabetic retina, both iNOS and B1R contribute to inflammation, oxidative...

Full description

Bibliographic Details
Main Authors: Rahmeh Othman, Elvire Vaucher, Réjean Couture
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-03-01
Series:Frontiers in Pharmacology
Subjects:
Online Access:https://www.frontiersin.org/article/10.3389/fphar.2019.00300/full
_version_ 1818935792589864960
author Rahmeh Othman
Rahmeh Othman
Elvire Vaucher
Réjean Couture
author_facet Rahmeh Othman
Rahmeh Othman
Elvire Vaucher
Réjean Couture
author_sort Rahmeh Othman
collection DOAJ
description Compelling evidence suggests a role for the inducible nitric oxide synthase, iNOS, and the bradykinin type 1 receptor (B1R) in diabetic retinopathy, including a possible control of the expression and activity of iNOS by B1R. In diabetic retina, both iNOS and B1R contribute to inflammation, oxidative stress, and vascular dysfunction. The present study investigated whether inhibition of iNOS has any impact on inflammatory/oxidative stress markers and on the B1R-iNOS expression, distribution, and action in a model of type I diabetes. Diabetes was induced in 6-week-old Wistar rats by streptozotocin (65 mg.kg-1, i.p.). The selective iNOS inhibitor 1400W (150 μg.10 μl-1) was administered twice a day by eye-drops during the second week of diabetes. The retinae were collected 2 weeks after diabetes induction to assess the protein and gene expression of markers by Western blot and qRT-PCR, the distribution of iNOS and B1R by fluorescence immunocytochemistry, and the vascular permeability by the Evans Blue dye technique. Diabetic retinae showed enhanced expression of iNOS, B1R, carboxypeptidase M (involved in the biosynthesis of B1R agonists), IL-1β, TNF-α, vascular endothelium growth factor A (VEGF-A) and its receptor, VEGF-R2, nitrosylated proteins and increased vascular permeability. All those changes were reversed by treatment with 1400W. Moreover, the additional increase in vascular permeability in diabetic retina induced by intravitreal injection of R-838, a B1R agonist, was also prevented by 1400W. Immunofluorescence staining highlighted strong colocalization of iNOS and B1R in several layers of the diabetic retina, which was prevented by 1400W. This study suggests a critical role for iNOS and B1R in the early stage of diabetic retinopathy. B1R and iNOS appear to partake in a mutual auto-induction and amplification loop to enhance nitrogen species formation and inflammation in diabetic retina. Hence, B1R-iNOS axis deserves closer scrutiny in targeting diabetic retinopathy.
first_indexed 2024-12-20T05:25:48Z
format Article
id doaj.art-773e1c7cc24d4d5c996103b68cde6ff7
institution Directory Open Access Journal
issn 1663-9812
language English
last_indexed 2024-12-20T05:25:48Z
publishDate 2019-03-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Pharmacology
spelling doaj.art-773e1c7cc24d4d5c996103b68cde6ff72022-12-21T19:51:53ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122019-03-011010.3389/fphar.2019.00300444220Bradykinin Type 1 Receptor – Inducible Nitric Oxide Synthase: A New Axis Implicated in Diabetic RetinopathyRahmeh Othman0Rahmeh Othman1Elvire Vaucher2Réjean Couture3School of Optometry, University of Montreal, Montreal, QC, CanadaDepartment of Pharmacology and Physiology, University of Montreal, Montreal, QC, CanadaSchool of Optometry, University of Montreal, Montreal, QC, CanadaDepartment of Pharmacology and Physiology, University of Montreal, Montreal, QC, CanadaCompelling evidence suggests a role for the inducible nitric oxide synthase, iNOS, and the bradykinin type 1 receptor (B1R) in diabetic retinopathy, including a possible control of the expression and activity of iNOS by B1R. In diabetic retina, both iNOS and B1R contribute to inflammation, oxidative stress, and vascular dysfunction. The present study investigated whether inhibition of iNOS has any impact on inflammatory/oxidative stress markers and on the B1R-iNOS expression, distribution, and action in a model of type I diabetes. Diabetes was induced in 6-week-old Wistar rats by streptozotocin (65 mg.kg-1, i.p.). The selective iNOS inhibitor 1400W (150 μg.10 μl-1) was administered twice a day by eye-drops during the second week of diabetes. The retinae were collected 2 weeks after diabetes induction to assess the protein and gene expression of markers by Western blot and qRT-PCR, the distribution of iNOS and B1R by fluorescence immunocytochemistry, and the vascular permeability by the Evans Blue dye technique. Diabetic retinae showed enhanced expression of iNOS, B1R, carboxypeptidase M (involved in the biosynthesis of B1R agonists), IL-1β, TNF-α, vascular endothelium growth factor A (VEGF-A) and its receptor, VEGF-R2, nitrosylated proteins and increased vascular permeability. All those changes were reversed by treatment with 1400W. Moreover, the additional increase in vascular permeability in diabetic retina induced by intravitreal injection of R-838, a B1R agonist, was also prevented by 1400W. Immunofluorescence staining highlighted strong colocalization of iNOS and B1R in several layers of the diabetic retina, which was prevented by 1400W. This study suggests a critical role for iNOS and B1R in the early stage of diabetic retinopathy. B1R and iNOS appear to partake in a mutual auto-induction and amplification loop to enhance nitrogen species formation and inflammation in diabetic retina. Hence, B1R-iNOS axis deserves closer scrutiny in targeting diabetic retinopathy.https://www.frontiersin.org/article/10.3389/fphar.2019.00300/fulldiabetic retinopathybradykinin type 1 receptorinducible nitric oxide synthasekallikrein-kinin systeminflammationoxidative stress
spellingShingle Rahmeh Othman
Rahmeh Othman
Elvire Vaucher
Réjean Couture
Bradykinin Type 1 Receptor – Inducible Nitric Oxide Synthase: A New Axis Implicated in Diabetic Retinopathy
Frontiers in Pharmacology
diabetic retinopathy
bradykinin type 1 receptor
inducible nitric oxide synthase
kallikrein-kinin system
inflammation
oxidative stress
title Bradykinin Type 1 Receptor – Inducible Nitric Oxide Synthase: A New Axis Implicated in Diabetic Retinopathy
title_full Bradykinin Type 1 Receptor – Inducible Nitric Oxide Synthase: A New Axis Implicated in Diabetic Retinopathy
title_fullStr Bradykinin Type 1 Receptor – Inducible Nitric Oxide Synthase: A New Axis Implicated in Diabetic Retinopathy
title_full_unstemmed Bradykinin Type 1 Receptor – Inducible Nitric Oxide Synthase: A New Axis Implicated in Diabetic Retinopathy
title_short Bradykinin Type 1 Receptor – Inducible Nitric Oxide Synthase: A New Axis Implicated in Diabetic Retinopathy
title_sort bradykinin type 1 receptor inducible nitric oxide synthase a new axis implicated in diabetic retinopathy
topic diabetic retinopathy
bradykinin type 1 receptor
inducible nitric oxide synthase
kallikrein-kinin system
inflammation
oxidative stress
url https://www.frontiersin.org/article/10.3389/fphar.2019.00300/full
work_keys_str_mv AT rahmehothman bradykinintype1receptorinduciblenitricoxidesynthaseanewaxisimplicatedindiabeticretinopathy
AT rahmehothman bradykinintype1receptorinduciblenitricoxidesynthaseanewaxisimplicatedindiabeticretinopathy
AT elvirevaucher bradykinintype1receptorinduciblenitricoxidesynthaseanewaxisimplicatedindiabeticretinopathy
AT rejeancouture bradykinintype1receptorinduciblenitricoxidesynthaseanewaxisimplicatedindiabeticretinopathy